AT509045B1 - Verbindungen zur behandlung von asthma bronchiale - Google Patents

Verbindungen zur behandlung von asthma bronchiale Download PDF

Info

Publication number
AT509045B1
AT509045B1 AT0012210A AT1222010A AT509045B1 AT 509045 B1 AT509045 B1 AT 509045B1 AT 0012210 A AT0012210 A AT 0012210A AT 1222010 A AT1222010 A AT 1222010A AT 509045 B1 AT509045 B1 AT 509045B1
Authority
AT
Austria
Prior art keywords
hydrazide
epo
phenylaminoethane
fluoro
compounds
Prior art date
Application number
AT0012210A
Other languages
German (de)
English (en)
Other versions
AT509045A4 (de
Original Assignee
Planta Naturstoffe Vertriebsges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0012210A priority Critical patent/AT509045B1/de
Application filed by Planta Naturstoffe Vertriebsges M B H filed Critical Planta Naturstoffe Vertriebsges M B H
Priority to EP11704168.1A priority patent/EP2528595B1/de
Priority to BR112012018772A priority patent/BR112012018772A2/pt
Priority to SG2012056172A priority patent/SG182786A1/en
Priority to MX2012008815A priority patent/MX2012008815A/es
Priority to CA2788326A priority patent/CA2788326A1/en
Priority to US13/578,516 priority patent/US20130065962A1/en
Priority to CN201510244522.0A priority patent/CN104958286B/zh
Priority to JP2012550265A priority patent/JP5788907B2/ja
Priority to AU2011208939A priority patent/AU2011208939B2/en
Priority to KR1020127022355A priority patent/KR20120128644A/ko
Priority to CN201180016552.6A priority patent/CN102858329B/zh
Priority to EP15173989.3A priority patent/EP2965755A1/de
Priority to PCT/AT2011/000050 priority patent/WO2011091461A1/de
Application granted granted Critical
Publication of AT509045B1 publication Critical patent/AT509045B1/de
Publication of AT509045A4 publication Critical patent/AT509045A4/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0012210A 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale AT509045B1 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
JP2012550265A JP5788907B2 (ja) 2010-01-29 2011-01-28 疾患の治療に使用される化合物
SG2012056172A SG182786A1 (en) 2010-01-29 2011-01-28 Compounds for use in the treatment of diseases
MX2012008815A MX2012008815A (es) 2010-01-29 2011-01-28 Compuestos para uso en el tratamiento de enfermedades.
CA2788326A CA2788326A1 (en) 2010-01-29 2011-01-28 Compounds for use in the treatment of diseases
US13/578,516 US20130065962A1 (en) 2010-01-29 2011-01-28 Compounds For Use In The Treatment Of Diseases
EP11704168.1A EP2528595B1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen
BR112012018772A BR112012018772A2 (pt) 2010-01-29 2011-01-28 composto, composição farmacêutica e uso de um composto
AU2011208939A AU2011208939B2 (en) 2010-01-29 2011-01-28 Compounds for use in the treatment of diseases
KR1020127022355A KR20120128644A (ko) 2010-01-29 2011-01-28 질환의 치료에 사용하기 위한 화합물
CN201180016552.6A CN102858329B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物
EP15173989.3A EP2965755A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen
CN201510244522.0A CN104958286B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale

Publications (2)

Publication Number Publication Date
AT509045B1 true AT509045B1 (de) 2011-06-15
AT509045A4 AT509045A4 (de) 2011-06-15

Family

ID=43707937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale

Country Status (12)

Country Link
US (1) US20130065962A1 (enExample)
EP (2) EP2965755A1 (enExample)
JP (1) JP5788907B2 (enExample)
KR (1) KR20120128644A (enExample)
CN (2) CN104958286B (enExample)
AT (1) AT509045B1 (enExample)
AU (1) AU2011208939B2 (enExample)
BR (1) BR112012018772A2 (enExample)
CA (1) CA2788326A1 (enExample)
MX (1) MX2012008815A (enExample)
SG (1) SG182786A1 (enExample)
WO (1) WO2011091461A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302177A1 (en) * 2012-08-10 2015-03-26 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
WO1992017065A2 (en) 1991-04-01 1992-10-15 Duke University Method of inhibiting fibrosis
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
WO2000015215A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
US6610715B1 (en) 1999-05-28 2003-08-26 Cheil Jedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
WO2005085185A1 (en) 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
PT2061765E (pt) * 2006-09-01 2015-02-06 Senhwa Biosciences Inc Moduladores de serina-treonina-proteína-quinase e de parp
BRPI0809974A2 (pt) 2007-03-30 2014-10-07 Sanofi Aventis Compostos de pirimidina hidrazida como inibidores de pgds
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
TWI485134B (zh) * 2009-05-04 2015-05-21 波麥堤克生化科學公司 取代的芳族化合物及其藥學用途

Also Published As

Publication number Publication date
US20130065962A1 (en) 2013-03-14
EP2528595B1 (de) 2015-08-05
AU2011208939B2 (en) 2015-07-09
CA2788326A1 (en) 2011-08-04
SG182786A1 (en) 2012-09-27
CN102858329A (zh) 2013-01-02
JP5788907B2 (ja) 2015-10-07
JP2013518061A (ja) 2013-05-20
CN104958286B (zh) 2018-01-05
BR112012018772A2 (pt) 2016-04-12
AU2011208939A1 (en) 2012-08-30
MX2012008815A (es) 2012-11-23
CN102858329B (zh) 2015-06-17
KR20120128644A (ko) 2012-11-27
CN104958286A (zh) 2015-10-07
AT509045A4 (de) 2011-06-15
WO2011091461A1 (de) 2011-08-04
EP2528595A1 (de) 2012-12-05
EP2965755A1 (de) 2016-01-13

Similar Documents

Publication Publication Date Title
EP1272201B1 (de) Verwendung von kompatiblen soluten als substanzen mit radikalfangenden eigenschaften
AT509045B1 (de) Verbindungen zur behandlung von asthma bronchiale
EP2380569B1 (de) Osmolyte zur Reduzierung der Nebenwirkungen von Steroiden oder Antihistaminika
EP2656850A2 (en) Oligonucleotides for the treatment or alleviation of edema
US20120070423A1 (en) Oral composition and method of forming and using same
EP1941880B1 (en) Lotion preparation containing pyridonecarboxylic acid derivative
KR101828631B1 (ko) 라파마이신 및 미코페놀산을 유효성분으로 포함하는 아토피 피부염 예방 및 치료용 조성물
DE102016113018A1 (de) Pharmazeutische Verwendung von beta-D-Mannuronsäure
EP3675814A1 (de) Zusammensetzung zur topischen behandlung von nicht-mikroorganismus-verursachten entzündlichen haut- und schleimhauterkrankungen
KR101342851B1 (ko) 신규한 피토스핑고신 유도체 및 이를 포함하는 염증성 피부질환, 자가면역질환 및 피부과다각화증질환 예방 및 치료용 조성물
ATE465254T1 (de) Verbindung, zusammensetzung und verfahren zur behandlung von entzündlichen und entzündungs- verwandten erkrankungen
US20250100963A1 (en) Sulfonated and phosphorylated aromatic molecules
JP6294773B2 (ja) 口腔粘膜疾患の予防または治療用経口製剤
WO2019141674A1 (de) Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel
JP3120965B2 (ja) 水虫外用薬
WO2018233884A1 (de) Cineolhaltige zusammensetzung für die behandlung von nasalen erkrankungen
CN118161473A (zh) Isrib在制备防治缺血性脑卒中药物中的应用
RU2270046C2 (ru) Способ лечения микотических заболеваний уха
CN119925605A (zh) Mpo抑制剂在制备抗炎剂或创面愈合促进剂中的应用
Dzeman AN EXPERIENCE OF USING ERBISOL® IN DENTISTRY
CN109646413A (zh) 一种奥美钠镁片

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20170129